Pay as you go. Fixed prices. No subscriptions
We won’t overcharge you through a subscription model. Our one off economical prices remain fixed all the time
Pay as you go. Fixed prices. No subscriptions
We won’t overcharge you through a subscription model. Our one off economical prices remain fixed all the time
Start Wegovy weight management treatment with specialist review and ongoing support.
Body‑mass criteria:
Alongside lifestyle change
Structured assessment
Clinical decision‑making
Wegovy will be ruled out in certain situations, including if you:
In clinical studies, WeightFall patients lost more weight, in less time.¹
Your BMI Results:
You share your health and medication history.
A clinician will check your answers and submitted photos.
We confirm if Wegovy is appropriate for you.
Check‑ins every 3 weeks to review side effects, see how your current Wegovy dose feels, and decide whether to maintain, adjusting treatment.
Wegovy is a prescription-only weight loss injection used as part of a medicated weight management programme for adults living with obesity or overweight and related health conditions.
It contains Semaglutide, which acts on gut hormone receptors involved in appetite and blood‑sugar control. It is used alongside diet and physical‑activity changes and is only considered where clinically appropriate.
Any decision to start or continue treatment is made by a qualified prescriber after medical review.
Reduces appetite:
Wegovy acts on areas of the brain that regulate hunger, helping you feel fuller sooner and reducing the urge to overeat.
Curbs cravings:
Protects the heart:
Proven results:
Wegovy is one of the most widely studied prescription treatments for adults living with overweight or obesity. When used alongside healthy changes to eating and activity, research shows it can help many people achieve meaningful weight loss.
In clinical studies, around 86% of people lost at least 5% of their body weight, and about half lost 15% or more ¹ when using Wegovy as part of a structured weight-management plan. Other specialist clinic data also suggests that people taking semaglutide at obesity treatment doses lost around 6% of their weight within three months, increasing to around 11% by six months. ²
Longer-term research indicates that weight loss with semaglutide can be maintained over time, with many people continuing to keep weight off compared with those not using treatment. Alongside weight reduction, some people also experience improvements in waist size and health markers linked to excess weight.
Everyone responds differently. Some people notice steady changes over time, while others may see more modest results. Your clinician will review your progress regularly and will only recommend continuing treatment if it is providing meaningful benefit for you.
Why Choose
Focused, clinician-led weight management service to support you long term and not just a quick fix. Our clinical team consists of clinicians specialised in GLP-1 treatments and are experienced in building you a tailored weight management plan.
It’s more than just weight loss.
Dosage
Pricing
Review
Status
0.25mg
£85
Every 3 weeks
Starting dose
0.5mg
£85
Every 3 weeks
Titration dose
1mg
£90
Every 3 weeks
Possible maintenance dose
1.7mg
£139
Every 3 weeks
Possible maintenance dose
Feature
Wegovy (semaglutide)
Mounjaro (tirzepatide)
Dosage range
Typically increased from 0.25 mg up to 2.4 mg once weekly, following a step‑up schedule.
Typically increased from 2.5 mg up to 15 mg once weekly, following a structured titration schedule.
How often you take it
Once a week, on the same day each week.
Once a week, on the same day each week.
How long you can take it
Licensed for long‑term use for weight management under ongoing medical supervision.
Licensed for long‑term use for weight management under ongoing medical supervision.
How it works
GLP‑1 receptor agonist that curbs appetite, slows stomach emptying and supports blood‑sugar control to help reduce calorie intake.
Dual GIP and GLP‑1 receptor agonist ("twincretin") that suppresses appetite, reduces cravings and improves blood‑sugar control, with a stronger effect on metabolic pathways.
Administration
Once‑weekly self‑injectable pen used into the fatty layer under the skin (abdomen, thigh or upper arm).
Once‑weekly self‑injectable pen used into the fatty layer under the skin (abdomen, thigh or upper arm).
Price range at WeightFall
From £85 per month for Wegovy.
From £149 per month for Mounjaro.
Suitable for
Adults who meet Wegovy eligibility criteria (for example certain BMI thresholds and weight‑related health conditions) and for whom a GLP‑1‑only medicine is appropriate.
Adults who meet Mounjaro eligibility criteria and where a clinician feels a dual‑hormone medicine is suitable, particularly when additional metabolic support is needed.
Typical weight‑loss seen in trials
Many people achieved around 15–20% body‑weight reduction when Wegovy was combined with diet and activity changes.
Many people achieved around 15–23% body‑weight reduction at higher doses when Mounjaro was combined with diet and activity changes.
